Dana Aftab

EVP Dana Aftab sold 43,451 shares of EXEL at $50.35 on 2026-05-26 ($2.2M), retaining 594,741 shares; stock now at $51.45 near 52-week high.

Dana Aftab, EVP of Research and Development, disposed of 43,451 shares (6.8% of pre-transaction holdings) at $50.35, leaving him with 594,741 shares post-transaction. The sale occurred as EXEL trades near its 52-week high of $51.63, having risen 14.5% over 30 days and 16.8% over 90 days. His same-ticker history at EXEL shows mixed outcomes: 4 of 5 prior sales preceded positive 90-day returns (poorly timed from a sell perspective), while only 1 of 5 was well-timed (negative 90-day return). The company's fundamentals remain solid with $610.8M in latest-quarter revenue, $210.5M net income, and a modest 15.50 P/E ratio in a $12.9B market cap, though annual revenue growth is measured at 7.0%. The sale lacks material context flags but occurs in a rising-price environment where the insider's historical selling record at this ticker has not successfully preceded declines.

EVP R&D Aftab Dana sells 47,918 EXEL shares at $44.50; holds 616,106 post-transaction

Aftab Dana, EVP of Research and Development, sold 47,918 shares of EXELIXIS at $44.50 on 2026-02-24, reducing his holdings from 664,024 to 616,106 shares (-7.2%). The sale represents a substantial transaction at $2,132,351.00 in absolute terms, though the percentage reduction is moderate. His prior trades at EXEL show mixed outcomes: 1 of 4 prior measurable sells occurred before subsequent price declines, with the most recent sale just five days prior on 2026-02-19 (outcome not yet measurable). His cross-ticker track record shows a 20.00% well-timed rate across 6 prior sells with an average 90-day return of +17.2%, indicating his sales have more often followed price advances than preceded declines. EXELIXIS trades near its 52-week high ($46.61) with solid fundamentals—$597.8M quarterly revenue, $193.6M net income, 7.0% annual revenue growth, and a 15.38 P/E ratio—providing no obvious valuation pressure that would explain the sale discretionary rationale.

EVP Aftab Dana sold 29,873 shares of EXEL at $44.35 on 2026-02-19; retains 664,024 shares post-sale.

Aftab Dana, EVP of Research and Development, executed an open-market sale of 29,873 shares at $44.35, reducing holdings by 4.3% to 664,024 shares. The transaction occurred near the 52-week high ($46.61), with the current price at $44.01 reflecting modest recent weakness (-5.6% from peak). Across his prior five sales at EXEL, Dana's timing has been mixed: only 1 of 5 prior sales were well-timed (stock declined post-sale), while the other four preceded positive 90-day returns, suggesting a pattern of selling into strength without consistently predicting subsequent downside. At the fundamentals level, EXEL trades at a P/E of 15.28 with $597.8M in quarterly revenue and $193.6M in net income, positioning the company as profitable and moderately valued; the 7.0% annual revenue growth rate is modest rather than concerning.

EXEL EVP R&D Aftab Dana sells 48,383 shares at $42.50; cross-ticker timing history weak (25% well-timed rate, +20.6% avg 90d return).

Aftab Dana, EVP of Research and Development at Exelixis, sold 48,383 shares at $42.50 on 2025-11-11, reducing holdings from 713.2K to 664.8K shares (-6.8%). The stock currently trades at $42.35, having risen 7.2% over 30 days and 10.6% over 90 days from the transaction date. Historically, Dana's cross-ticker sell activity has shown mixed timing: his prior 4 open-market sales averaged a +20.6% 90-day return, meaning the stock typically rose after his exits—a poorly-timed pattern reflected in a 25% well-timed rate. At Exelixis specifically, Dana executed 4 prior sells: only 1 of 4 resulted in a negative 90-day return, suggesting limited predictive accuracy at this ticker. With the company reporting strong fundamentals ($597.8M quarterly revenue, +18.5% annual growth, $193.6M net income), the sale appears disconnected from deteriorating business conditions rather than a forward-looking signal of material concern.

Aftab Dana (CSO/EVP) sold 26,987 shares of EXEL at $36.75; holds 511,908 shares post-sale as stock near 52-week high.

Aftab Dana, serving as CSO/EVP Disc & Trans Research, sold 26,987 shares at $36.75 on 2025-02-24, reducing his position by 5.0% to 511,908 shares. The sale occurred with EXEL trading near its 52-week high of $37.53 (stock up 14.7% over 30 days), suggesting execution during a strong recent price run. At the same-ticker level, Dana's prior three EXEL sales have shown mixed timing outcomes: one well-timed (90d -6.1%), and two poorly-timed (90d +34.0% and +39.1%), indicating he captured only 1 of 3 prior sales before subsequent gains. Fundamentally, EXEL exhibits solid health with a 13.45 P/E, +18.5% annual revenue growth, and $118.0M net income on $539.5M quarterly revenue, which does not suggest financial distress. The sale appears discretionary rather than part of a systematic reduction plan, and the timing coincides with recent strength rather than a contrarian entry point.

CSO Aftab Dana sold 96,986 shares of EXEL at $35.00 on 2024-11-05; stock now at $35.80 near 52-week high after +41.0% in 30 days.

Aftab Dana, CSO/EVP Disc & Trans Research, sold 96,986 shares worth $3,394,510.00 at $35.00 on 2024-11-05, reducing holdings by 16.3% to 498,945 shares. The sale occurred as EXEL stock traded near its 52-week high of $35.80, having rallied +41.0% over the prior 30 days and +32.7% over 90 days. His prior two sales at EXEL (2024-08-12 and 2024-08-07) showed mixed timing outcomes; the August 7 sale delivered a +39.1% 90-day return (poorly timed, as the stock rose after), while his cross-ticker track record across 2 prior sells shows an average 90-day return of +39.1% with 0.00% well-timed rate—indicating his sell decisions have consistently missed subsequent rallies. The timing of this sale into a rapid price appreciation and extended high valuation (P/E of 21.83) merits monitoring against his historical pattern.

Aftab Dana (CSO/EVP) sold 20,883 shares of EXEL at $27.06 on 2024-08-12, reducing holdings by 4.0% to 500,107 shares.

Aftab Dana, Chief Strategy Officer and EVP of Discrete & Translational Research at Exelixis, sold 20,883 shares at $27.06, a modest 4.0% reduction in his 521.0K share position. The transaction occurred near the 52-week high ($27.17), with the stock currently trading at $26.30. Exelixis fundamentals remain solid—the company posted $637.2M in quarterly revenue, $226.1M net income, and a P/E of 21.38—and the stock has appreciated +16.6% over 30 days and +23.9% over 90 days. This is Dana's second open-market sale at Exelixis within five days, following a sale on 2024-08-07; his broader cross-ticker history shows minimal prior selling activity. The modest size and near-peak timing warrant observation as the company benefits from recent momentum, though the fundamentals do not suggest distress.

CSO Aftab Dana sold 95,000 shares of EXEL at $25.00 on 2024-08-07, reducing holdings by 15.4% to 521,000 shares.

Aftab Dana, CSO/EVP of Disclosure & Transactions Research, executed a single sale of 95,000 shares valued at $2,375,000.00 at $25.00 per share, reducing his post-transaction holdings to 520,990 shares. The sale occurred when the stock was near its 52-week high of $27.17 (currently $26.97, -0.7% from high), and the timing aligns with recent strong price momentum: the stock has appreciated 22.3% over 30 days and 26.2% over 90 days. EXEL fundamentals remain solid with recent quarterly revenue of $637,178,000.00, net income of $226,116,000.00, annual revenue growth of 13.6%, and a P/E of 21.93 at a $7.7B market cap. No predefined trading plan or scheduled transaction pattern is noted, leaving the discretionary nature and business rationale for this specific sale transaction opaque to external observers.